Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC
May 29th 2020The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel.
Savolitinib Induces Encouraging Efficacy, Safety in MET-Driven Papillary Renal Cell Carcinoma
May 29th 2020A phase III study presented the 2020 ASCO Virtual Scientific Program showed encouraging efficacy data suggesting savolitinib could be used to treat patients with MET-driven papillary renal cell carcinoma.